Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : QLT PhotoTherapeutics (QLTI) -- Ignore unavailable to you. Want to Upgrade?

To: hoyasaxa who wrote (864)	4/6/2000 11:58:00 AM
From: Ian@SI	Read Replies (1) \| Respond to of 1321

There was an exact date set for the subcommittee meeting which led to the recommendation that Visudyne be approved without restrictions. There is not precise date, nor any specific meeting. Rather the FDA and QLT have been working on answering a list of outstanding questions and issues which the FDA had. QLT has gone through the checklist with flying colours. About 2 weeks ago, Duncan Stewart indicated there was 1 question left on the list. Thus, full approval is imminent. If you can give us the exact date and time that this will occur, just send it to me by PM. ;-) Ian